NCT01990521Active, not recruiting
Prostate Screening Study Using MRI in BRCA Carriers
Screening Male BRCA Mutation Carriers: Effectiveness of Multispectral 3T Magnetic Resonance Imaging
Source: ClinicalTrials.gov · Last updated 9 Sept 2025
Brief summary (registry, in English)
Men with a BRCA1 or BRCA2 mutation are at increased risk for early onset, aggressive prostate cancer compared to men in the general population. Standard of care screening for men with a BRCA mutation includes PSA testing and digital rectal examination (DRE), the same as with men in the general population. This study is being done to assess whether there is value in using MRI as a screening tool to detect prostate cancer at an earlier stage than may otherwise be detected using standard of care screening (PSA, DRE). It is unclear whether MRI has utility as a screening tool in this specific population at high risk for aggressive disease.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 15 Nov 2013
- Start date
- Jan 2014
- Primary completion date
- Sept 2025
- Lead sponsor
- Toronto Sunnybrook Regional Cancer Centre
- Diseases
- Prostate cancer
- NCT number
- NCT01990521
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Jan 2014 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindication to receiving low molecular weight MRI contrast agent
- Previously diagnosed with prostate cancer
Other
- Claustrophobia
- Contraindication to MRI
Who the study is looking for
- Enrolled in the Male Hereditary Cancer Research Program at Sunnybrook Health Sciences Center.
- Have positive genetic testing for a pathogenic BRCA1 or BRCA2 mutation.
- Clinically eligible for and willing to undergo ultrasound biopsy within 4 weeks after the MRI.
- Be 50 years of age or older.
Age in the registry: 50 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sunnybrook Odette Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.